FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1657646300> ?p ?o ?g. }

• W1657646300 endingPage "300" @default.
• W1657646300 startingPage "293" @default.
• W1657646300 abstract "HomeStrokeVol. 47, No. 1Mouse Models of Cerebral Arteriovenous Malformation Free AccessResearch ArticlePDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissionsDownload Articles + Supplements ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toSupplemental MaterialFree AccessResearch ArticlePDF/EPUBMouse Models of Cerebral Arteriovenous Malformation Corinne M. Nielsen, PhD, Lawrence Huang, PhD, Patrick A. Murphy, PhD, Michael T. Lawton, MD and Rong A. Wang, PhD Corinne M. NielsenCorinne M. Nielsen From the Laboratory for Accelerated Vascular Research, Division of Vascular Surgery, Department of Surgery (C.M.N., L.H., P.A.M., R.A.W.) and Department of Neurosurgery (M.T.L.), University of California, San Francisco; and Department of Biology, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge (P.A.M.). *Drs Nielsen and Huang contributed equally. Search for more papers by this author , Lawrence HuangLawrence Huang From the Laboratory for Accelerated Vascular Research, Division of Vascular Surgery, Department of Surgery (C.M.N., L.H., P.A.M., R.A.W.) and Department of Neurosurgery (M.T.L.), University of California, San Francisco; and Department of Biology, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge (P.A.M.). *Drs Nielsen and Huang contributed equally. Search for more papers by this author , Patrick A. MurphyPatrick A. Murphy From the Laboratory for Accelerated Vascular Research, Division of Vascular Surgery, Department of Surgery (C.M.N., L.H., P.A.M., R.A.W.) and Department of Neurosurgery (M.T.L.), University of California, San Francisco; and Department of Biology, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge (P.A.M.). Search for more papers by this author , Michael T. LawtonMichael T. Lawton From the Laboratory for Accelerated Vascular Research, Division of Vascular Surgery, Department of Surgery (C.M.N., L.H., P.A.M., R.A.W.) and Department of Neurosurgery (M.T.L.), University of California, San Francisco; and Department of Biology, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge (P.A.M.). Search for more papers by this author and Rong A. WangRong A. Wang From the Laboratory for Accelerated Vascular Research, Division of Vascular Surgery, Department of Surgery (C.M.N., L.H., P.A.M., R.A.W.) and Department of Neurosurgery (M.T.L.), University of California, San Francisco; and Department of Biology, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge (P.A.M.). Search for more papers by this author Originally published8 Sep 2015https://doi.org/10.1161/STROKEAHA.115.002869Stroke. 2016;47:293–300Other version(s) of this articleYou are viewing the most recent version of this article. Previous versions: January 1, 2015: Previous Version 1 Characteristics of Human Brain AVM and Mouse Models of the DiseaseArteriovenous (AV) malformation (AVM) is a vascular anomaly capable of both hemorrhagic and ischemic insults, leading to seizures, headaches, stroke, and even death.1 BAVM prevalence is estimated at 0.05%,2 often occurring in young people between 20 and 40 years of age.3 BAVMs account for 50% of hemorrhagic stroke in children4 and 1% to 2% of all strokes in the population.5 Brain AVMs (BAVMs) can cause life-threatening intracerebral hemorrhage (Figure 1).6 Fifty percent of patients are first diagnosed on intracerebral hemorrhage,1 with 1% and 5% annual hemorrhage rate for previously unruptured and ruptured AVMs, respectively.7,8 After BAVM rupture, reported mortality rates range from to 15% to 29%,7 and long-term morbidity rates range from 16% to 56%.1,9 Thus, BAVM is defined by vascular features and accompanying neurological deficits.1Download figureDownload PowerPointFigure 1. Features of human brain arteriovenous malformation (AVM). A, An AVM is visualized on the lateral temporal surface of a human brain. 5, 6 are landmarks placed by surgeon; 40 shows Broca's area; 48 shows Wernicke's area. B, Left internal carotid artery (ICA) angiography (lateral view) reveals a left lateral temporal AVM with a large feeding artery and draining vein. C, Cartoon of this subtype (lateral view), indicating feeding arteries and draining veins. ATA indicates anterior temporal artery. Reprinted from Lawton6 with permission of the publisher. Copyright © 2014, Thieme Medical Publishers.AVM is characterized by high-flow AV connections that shunt blood directly from arteries to veins, displacing intervening capillaries with a nidus of enlarged and tortuous vessels. BAVM clinical characteristics include (1) AV shunting, the presence of direct connections between arteries and veins, displacing intervening capillaries; (2) abnormally high blood flow through the feeding artery, AV shunt, and draining vein; (3) the presence of a focal nidus consisting of enlarged, tangled vessels; (4) intracerebral hemorrhage and ischemia and increased endothelial permeability; and (5) neurological deficits, including seizures, headache, unsteadiness, and stroke. Therefore, mouse models relevant to translational BAVM research should exhibit these anatomic, functional, and symptomatic features of the human disease.Two different approaches have led to progress in genetically engineered mouse models of BAVM (Table). Bedside-to-bench—heritable risk alleles in human patients have been mutated in mouse counterparts; conversely, Bench-to-bedside—genes identified in embryonic AV specification have also been mutated in mice to provide new insight into the human disease. Here, we provide an overview of mouse models of BAVM developed by both approaches (Table; Table I in the online-only Data Supplement).10–32Table. Genetic Mouse Models Exhibit Features of BAVMGenetic ManipulationDescription of ManipulationIncidence of BAVMPenetrance of BAVMDilated VesselsAV Shunts*High Flow*Nidus*Hemorrhage*Neurological Dysfunction*LethalityNonbrain AVMReferenceEng+/− (CD1 background)Embryonic germline heterozygous deletion………………………10Eng+/− (129/Ola background)Embryonic germline heterozygous deletion14%………………14% by 1 y✓10Eng+/− (129/Ola background)Embryonic germline heterozygous deletion25%………………25% by 2 y✓11Eng+/− (B6 or 129 background)Embryonic germline heterozygous deletion25–40 wk30%✓✓✓✓…………12Alk1+/−Embryonic germline heterozygous deletion40%✓…………✓…✓13Eng+/−+human recombinant VEGFEmbryonic germline heterozygous deletion+adult angiogenic stimulus2–4 wk post VEGF89%✓……✓…………14Eng+/−+AAV-VEGFEmbryonic germline heterozygousdeletion+adult angiogenic stimulusBy 6 wk post AAV✓…………………15Alk1+/−+AAV-VEGFEmbryonic germline heterozygous deletion+adult angiogenic stimulusby 6wk post AAV✓…………………15L1-Cre; Alk1fx/fxEndothelial cell deletion during embryonic development100%…✓…………Embryonic day 18.5✓16L1-Cre; Alk1fx/fxEndothelial cell deletion during embryonic developmentBy 5 d100%✓✓✓✓……5 d✓17Ad-Cre+Alk1fx/fx+AAV-VEGFLocal deletion in adults+angiogenic stimulusBy 8wk post AAV/Cre✓✓………………18Ad-Cre+Alk1Δ/fx+AAV-VEGFLocal deletion in adults/germline null+angiogenic stimulusBy 8wk post AAV/Cre✓✓………………19Ad-Cre+Engfx/fx+AAV-VEGFLocal deletion in adults+angiogenic stimulusBy 8wk post AAV/Cre✓…………………20Pdgfb(PAC)-CreERT2; Alk1fx/fx+AAV-VEGFEndothelial cell deletion in adults+angiogenic stimulus10 d post AAV/TAM✓✓……✓…6–13 d post TAM✓21Cdh5(PAC)-CreERT2; Engfx/fxEndothelial cell deletion at birth……………………✓22Cdh5(PAC)-CreERT2; Engfx/fxEndothelial cell deletion in adults……………………✓22R26-CreERT2; Alk1fx/fxGlobal deletion in adults100%………………9–21 d post TAM✓17R26-CreERT2; Engfx/fx+AAV-VEGFGlobal deletion in adults+angiogenic stimulus8 wk post AAV/TAM✓✓…✓✓……✓23R26-CreERT2; Engfx/fxGlobal deletion in adults…………………2 mo post TAM✓23R26-CreERT2; Engfx/fxGlobal deletion in adults…………………8–10 d post TAM✓24SM22α-Cre; Alk1fx/fxSmooth muscle cell deletion in adults10–15 wk✓………✓✓2–82 wk…25SM22α-Cre; Alk1fx/−Smooth muscle cell deletion in adults/germline null10–15 wks✓………✓✓2–58 wks…25SM22α-Cre; Engfx/fxSmooth muscle cell deletion in adults5 wk90%✓✓……✓…50% by 6 wk✓23Myh11-CreERT2; Engfx/fxSmooth muscle cell deletion in adults……………………✓24Scl-CreERT; Engfx/fxEndothelial cell deletion in adults…………………0% 1 mo post TAM✓24Scl-CreERT; Alk1fx/fxEndothelial cell deletion in adults……………………✓24NG2-CreERTM; Alk1fx/fx+ AAV-VEGFPericyte deletion in adults+angiogenic stimulus………………………21Tie2-tTA; TRE-Notch1*Constitutive activation in endothelial cells at 21 d100%…………………✓26Tie2-tTA; TRE-Notch4*Constitutive activation in endothelial cells at 21 d100%…………………✓26Tie2-tTA; TRE-Notch1*Constitutive activation in endothelial cells at birth14 d100%✓✓……✓✓……27Tie2-tTA; TRE-Notch4*Constitutive activation in endothelial cells at birth18 d100%✓✓✓✓✓✓36 d…27,28Tie2-tTA;TRE-Notch4* OFFConstitutive activation in endothelial cells OFF at 12 dBAVM regress from 24 h100% regressRegressRecoverNormalizeRegressRecoverRecoverPrevented…29Cdh5(PAC)-CreERT2; Rbpjfx/fxEndothelial cell deletion at birth14 d100%✓✓…✓✓✓21 d✓30Cdh5(PAC)-CreERT2; Alk1fx/fxEndothelial cell deletion at birth……………………✓31Cdh5(PAC)-CreERT2; Alk1fx/fxEndothelial cell deletion in adults……………………✓31Mgp−/−Embryonic germline homozygous deletionBy 4 wk100%✓✓……✓……✓32AAV indicates adeno-associated viral vectors; AVM, arteriovenous malformation; BAVM, brain AVM; TAM, tamoxifen; and VEGF, vascular endothelial growth factor.*Clinically defined features of BAVM.Bedside-to-Bench: Human Mutations Inspire Mouse Models of Hereditary Hemorrhagic Telangiectasia–Mediated AVMAlthough most BAVMs are sporadic with no known genetic lesions, about 5% are associated with autosomal-dominant disorders (Table II in the online-only Data Supplement). Hereditary hemorrhagic telangiectasia (HHT) is the most prevalent of these and is characterized by AVMs in multiple organs, including the brain.33 HHT is mainly caused by mutations in Endoglin (ENG) (HHT1), encoding a transforming growth factor-β–binding protein,33 and activin receptor-like kinase 1 (ACVRL1) (ALK1) (HHT2), encoding a cell-surface receptor for transforming growth factor-β ligands.34 Both genes are expressed primarily by endothelial cells (ECs), but how deficiencies in either ENG or ALK1 lead to AVM pathology remains unclear. In addition, mutations to MADH4, which encodes for Smad4, an effector of transforming growth factor-β signaling, cause a combined juvenile polyposis syndrome and HHT.35 HHT can also result from mutations in BMP936 and 2 unidentified genes on chromosome 5 (HHT3)37 and on chromosome 7 (HHT4).38 Furthermore, PTPN14, which encodes for a nonreceptor tyrosine phosphatase, shows genetic association with pulmonary AVMs in HHT.39 These studies of familial HHT have revealed that multiple, heritable genetic lesions can lead to HHT-related AVMs.Mutations in RASA1 and PTEN have been linked to AVM in humans. RASA1, which encodes for p120 Ras GTPase-activating protein (a negative regulator of Ras/MAPK pathway), is mutated in capillary malformation–AVM.40 Capillary malformation–AVM is an autosomal-dominant disorder that is characterized by cutaneous capillary malformations and AVMs, including BAVMs.40PTEN encodes a tumor suppressor in the phosphoinositide 3-kinase pathway. Mutations in PTEN cause Bannayan–Riley–Ruvalcaba and Cowden syndromes and result in AVMs as part of their clinical phenotype.41 Identification of these causal mutations holds promise for future discovery of molecular pathways attributable to AVMs.Experimental mouse models were engineered with targeted mutations in the Eng (HHT1) and Alk1 (HHT2) genes. Eng or Alk1 knockouts exhibit embryonic vascular defects, including dilated and fused artery–vein pairs and die in utero.42,43Eng+/− or Alk1+/− heterozygous mice are viable and develop characteristics of HHT during adulthood;10–13 however, features of BAVM, including AV shunts, niduses of dilated vessels, and rounded, misaligned EC nuclei, occur in 30% of Eng+/− mice aged 25 to 40 weeks, similar to BAVM incidence in HHT1 patients.12 Thus, loss of 1 allele of Eng or Alk1 is sufficient to induce BAVM in adult mice, but with incomplete penetrance.The incomplete penetrance and focal BAVM development in Eng+/− and Alk1+/− mice led to the hypothesis that these genetic perturbations require a second hit—a corroborating process or genetic lesion—in AVM formation. Data from human BAVM patients support the second hit hypothesis: (1) BAVM typically presents in adolescence or adulthood, even though patients harbor germline mutations44; (2) a high level of angiogenic signaling near human AVM suggests that AVM may be triggered by angiogenesis45; (3) somatic loss of heterozygosity has been observed in RASA1-mediated AVMs.46 The finding that a genetic perturbation leads to BAVM in immature/remodeling but not mature/quiescent mouse brains provides the first experimental evidence that angiogenic remodeling may be a permissive factor for AVM formation.26,28 Both classes of second hit candidates have been explored, resulting in more robust and tractable models of BAVM formation.Local delivery of vascular endothelial growth factor (VEGF) results in local vascular dysplasia in Eng+/− or Alk1+/− mice. Recombinant human VEGF injection into Eng+/− brains leads to microvascular abnormalities, including enlarged, tortuous, and clustered vessels, with 89% penetrance and 2- to 4-week latency.14 Similarly, focal adenoviral VEGF delivery into the cerebral cortex of Eng+/− and Alk1+/− adult mice results in abnormally enlarged capillaries and increased capillary density, with 6-week latency.15 Notably, vascular defects are more profound in Eng+/− mice than in the Alk1+/− mice.15 Together, these studies support the possibility that VEGF-induced angiogenic stimulus can be a second hit for vascular dysplasia in Eng+/− and Alk1+/− mice.The hypothesis that a somatic loss of heterozygosity increases AVM formation has been experimentally tested using genetic tools for tissue-specific, temporal gene deletion. Deletion of both alleles of Alk1 from embryos in a subset of Alk1 expressing cells results in late gestational or postnatal lethality with AVMs in the brain (Figure 2A),17,18,20 lung, and intestine.16,17 However, tamoxifen-dependent deletion of Alk1 from adult mice using R26-CreERT2 results in lung and intestinal AVMs, but is insufficient to induce BAVMs.17 Together, these studies suggest that deletion of both Alk1 alleles is sufficient to induce BAVM during development, but not during adulthood.Download figureDownload PowerPointFigure 2. Hereditary hemorrhagic telangiectasia (HHT) mutations lead to features of brain arteriovenous malformation (AVM) in mice. A, Entangled, tortuous AV shunts in latex dye–perfused L1-Cre; Alk1fx/fx P3 mouse brains. In Alk1fx/fx control brains, latex dye–labeled major arteries (left). In mutant brains, dye is found in veins and arteries (right). Reprinted from Park et al17 with permission of the publisher. Copyright © 2009, American Society for Clinical Investigation. B, In adult Alk1fx/fx mice, viral Cre and vascular endothelial growth factor (VEGF) induces large, tangled vessels near the injection site 8 weeks after virus delivery (left). Alk1 deletion by Ad-Cre, without AAV-VEGF, does not affect local vasculature (right). Reprinted from Walker et al18 with permission of the publisher. Copyright © 2011, John Wiley and Sons. C, In adult R26-CreERT2; Engfx/fx mice, global Eng deletion and focal delivery of AAV-VEGF induce tangled vessels and increased vessel dysplasia near the injection site (right, white arrow) 8 weeks post treatment, as shown by latex dye perfusion. Eng deletion without AAV-VEGF does not affect local vasculature (left). Reprinted from Choi et al20 with permission of the publisher. Copyright © 2014, Public Library of Science. Scale bars: (B) 100 µm; (C) 1 mm.Combination of local angiogenic stimulus and Alk1 or Eng deletion promotes BAVM formation in adult mice (refer to Table). Deletion of Alk1 or Eng, coupled with VEGF administration, results in signs of AVM, including enlarged and dysplastic vessels (Figure 2B and 2C),18–21 AV shunting,18,20 irregular vessel aggregates,18,20 and microhemorrhage.20,23 These studies show that the loss of either Alk1 or Eng alleles, in conjunction with angiogenic stimulation, may lead to AVM formation.Endothelial deletion of Alk1 or Eng, in combination with angiogenic stimulus, results in features of nonbrain AVM in mice. Endothelial Alk1 deletion in adult mice leads to gastrointestinal AVM and hemorrhage 6 to 14 days after induction of gene deletion.23,24 Deletion of Eng from postnatal endothelium leads to AV shunting and increased EC proliferation in the developing retina.22 However, angiogenic matrigel implantation or wounding is required to induce vascular defects in endothelial Eng-deficient skin.22,24 Thus, the loss of Alk1 or Eng from postnatal endothelium can result in nonbrain AVM under certain circumstances.Recent work has raised the possibility that HHT mutations in perivascular cells may also contribute to AVM. Mice with Alk1 deficiency in smooth muscle cells (SMCs, SM22α-Cre; Alk1fx/fx or SM22α-Cre; Alk1fx/−) exhibit characteristics of BAVM by 10 to 15 weeks of age.25 Both models, SM22α-Cre; Alk1fx/fx and SM22α-Cre; Alk1fx/−, develop tortuous vessels, large areas of hemorrhage, and hindlimb or whole body paralysis. Similarly, 90% of mice with SMC deletion of Eng during adulthood also develop characteristics of BAVM.20 Enlarged, tortuous vessels assembling into focal tangles are observed, as well as direct AV shunting. These studies raise the possibility that the loss of Eng or Alk1 from SMCs lead to AVM.However, these data remain controversial—SM22α-Cre–mediated recombination has been observed in some brain ECs,25 potentially confounding the conclusion that gene deletion is confined to the SMC compartment. Whether perivascular HHT mutations drive AVM formation remains questionable: (1) Alk1 or Eng deficiency in adult ECs, but not SMCs, induces AVM in a skin wound model24; (2) deletion of Alk1 from ECs, but not pericytes, along with focal delivery of VEGF leads to BAVM formation in adult mice.23 Together, these studies suggest that endothelial, but not perivascular, Alk1 or Eng deficiency can result in AVM in combination with VEGF stimulation. However, altered perivascular cell coverage is associated with BAVM in mice. After VEGF-induced angiogenesis in Alk1-deficient brains, fewer pericytes, decreased PDGFR-β (platelet-derived growth factor receptor-beta) expression, and fewer vessels expressing α-smooth muscle actin are observed, suggesting reduced smooth muscle coverage.23 The perivascular defects observed in animal models are similar to human AVM; however, the contribution of these defects to AVM progression remains unclear.Bench-to-Bedside: Mutations in the Notch Pathway Lead to Hallmarks of AVM in MiceInvestigations into the functions of genes regulating AV specification (Figure 3A)29 have led to potential roles in AVM formation. Perturbations to signaling pathways that disrupt normal AV specification often lead to vascular abnormalities that resemble AV shunting in mice (Table III in the online-only Data Supplement). Differential AV expression patterns of Notch receptors persist in adult endothelium, suggesting that they are important in maintaining AV specification in adult. Carlson et al26 first showed that the upregulation of Notch signaling in postnatal endothelium elicits AVM formation. Endothelial expression of a constitutively active Notch4 allele (Notch4*) in adult mice results in features of AVM in liver, skin, and uterus, but not in brain. Arterial marker expression is increased, suggesting arterialization of vessels in Notch4* adult mice. This seminal study opens the possibility that Notch, crucial in AV specification, may be important in AVM pathogenesis.Download figureDownload PowerPointFigure 3. Notch signaling regulates endothelial arteriovenous (AV) specification. A, Signaling pathways regulating AV specification. Arterial endothelial cell (EC) identity is prompted by the proangiogenic factor, vascular endothelial growth factor (VEGF). VEGF activates Notch signaling and leads to expression of the arterial marker Efnb2. Sox and Fox transcription factors contribute to Notch activation and arterial identity. Venous EC identity requires suppression of Notch signaling by the chicken ovalbumin upstream promoter transcription factor 2 (COUP-TFII). Inactivation of Notch permits expression of the venous marker Ephb4. B, In whole-mount brain, Ephb4tau-lacZ is expressed by venous (closed arrowheads), but not arterial (open arrowheads) vessels. C, Following endothelial Notch4* activation, Ephb4tau-lacZ is downregulated in veins and AV shunts. D, Four days post reversal of Notch4* activation, Ephb4tau-lacZ expression is restored in veins and regressing AV shunts (scale bars, 100 μm). Reprinted from Murphy et al29 with permission of the publisher. Copyright © 2012, American Association for the Advancement of Science.Endothelial expression of Notch4* in immature mice leads to hallmarks of BAVM.28 Vascular lesions were completely penetrant when Notch4* was turned on from birth, causing lethality by P36 lesions exhibited the hallmarks of human BAVM, including enlarged, tortuous vessels, AV shunting, increased flow in the feeding carotid arteries, nidus formation, hemorrhage, and ataxia (Figure 4A).27–29 Endothelial Notch4* increases arterial marker expression (Efnb2, Connexin40, Jagged1, Dll4) and decreases venous marker expression (Ephb4; Figure 3B and 3C), suggesting arterialization of the brain endothelium by Notch4*.28,29 Thus, unlike in adult brains, Notch4* is able to induce AVMs in immature brains, suggesting that immature brain vasculature is susceptible to Notch4*-induced AVM formation. Endothelial expression of constitutive Notch1 (Notch1*) in immature brains also leads to features of BAVM, indicating that increased activity of either Notch receptor is sufficient to cause BAVM.27Download figureDownload PowerPointFigure 4. Endothelial expression of constitutively active Notch leads to hallmarks of brain arteriovenous malformation (AVM). A, Endothelial expression of Notch4* induces enlarged, tangled blood vessels in cerebellum and midbrain as shown by vascular casting at P27 (right, arrowheads). Control brains exhibit normal vasculature (left). Reprinted from Murphy et al28 with permission of the publisher. Copyright © 2008, National Academy of Sciences. B, Notch4* initiates AV shunts through enlargement of capillary-like vessels, as shown by in vivo 2-photon imaging. Arrowheads indicate an AV shunt developing from a capillary diameter AV connection between P14 and P19. Reprinted from Murphy et al27 with permission of the publisher. Copyright © 2014, National Academy of Sciences. C, Repression of Notch4* decreases AV shunt diameter and decreases blood flow velocity, as shown by in vivo 2-photon imaging. Reprinted from Murphy et al29 with permission of the publisher. Copyright © 2012, American Association for the Advancement of Science. Scale bars: (B and C) 50 µm.In vivo time-lapse imaging of BAVM formation in Notch4* mice shows that AV shunts arise from microvessels with capillary-like diameter and blood flow profiles, without a significant increase in EC proliferation (Figure 4B).27 Clinical observations suggest that increased flow through low-resistance AV shunts encourages their growth, whereas stealing blood flow from adjacent higher resistance vessels.47 In this model, Notch4* permits steal and perpetuates a positive feedback loop, leading to selective growth of higher velocity at the expense of lower velocity AV connections.27 Thus, Notch4* (and presumably Notch1*) promotes the initiation and progression of BAVM in mice (Figure 4A).Conversely, blocking Notch signaling, via deletion of Rbpj, in postnatal endothelium also leads to features of BAVM in mice.30 Endothelial deletion of Rbpj at birth results in tortuous vessels, AV shunting, vessel aggregates, hemorrhage, and signs of neurological deficits by P14 in the brain. AV shunts show decreased Efnb2 and increased Ephb4 expression, suggesting acquisition of venous identity. Data from the gain- and loss-of-function Notch models are consistent with the model that tight regulation of Notch signaling is essential to prevent BAVM in mice.Crosstalk Between HHT and Notch Signaling PathwaysGene expression changes in HHT mutant mice suggest a link between HHT and Notch signaling pathways in AVM formation. Loss of Alk1 function results in abnormal arteriovenous marker expression, both in embryonic and postnatal mice.18,31,42 Alk1 signaling also synergizes with activated Notch in the endothelium to induce expression of Notch target genes.48 These data suggest that Alk1 may affect the expression of Notch downstream genes.Alk1/Notch crosstalk also functions in BAVM development. Deficiency of the extracellular bone morphogenetic protein (BMP) antagonist matrix Gla protein (MGP) leads to BAVM formation.32 Alk1 is a receptor for BMPs, and thus an increase in available BMP results in increased Alk1 signaling. Mgp−/− mice develop features of BAVM by 4 weeks of age, with enlarged cerebrovascular vessels, AV shunting, and hemorrhage (Figure 5).32 Analysis of AV marker expression shows increased Efnb2 and decreased Ephb4 expression in Mgp−/− brains. Notch ligands Jagged 1 and 2 are upregulated in Mgp−/− brains and Mgp−/− BAVMs, and heterozygous deletion of Jagged 1 and 2 in Mgp−/− mice suppresses BAVM formation. These findings extend to cultured brain ECs, where BMP9 is sufficient to activate Notch signaling and induce arterial marker expression.32 Together, these data suggest cooperation of Alk1 and Notch pathways in BAVM pathogenesis.Download figureDownload PowerPointFigure 5. Deficiency of bone morphogenetic protein (BMP) antagonist matrix Gla protein (MGP) leads to hallmarks of brain arteriovenous malformation (AVM). Microcomputed tomography imaging shows enlarged vessels and AV shunts in Mgp−/− but not Mgp+/− or Mgp+/+ mice. Colors represent vessel radii; asterisks represent AV connections. Scale bars: 1 mm. Reprinted from Yao et al32 with permission of the publisher. Copyright © 2013, National Academy of Sciences.Attempts in Therapeutic Treatment of AVMsMechanisms that underlie BAVM pathogenesis remain unclear, limiting the rational design of specific molecular interventions. To date, there are no specific or approved medical therapies to treat AVMs or to prevent AVM hemorrhage. Current treatment strategies include medical management49 and invasive procedures, such as surgical resection, stereotactic radiosurgery, and endovascular embolization.50,51 Treatment strategies aimed at inhibiting angiogenesis and maintaining vascular integrity have led to novel therapeutic approaches for the treatment of vascular malformations, including BAVMs (Table IV and text in the online-only Data Supplement). Further therapeutic development depends on an improved understanding of mechanisms underlying AVM pathogenesis, such as those uncovered using mouse models of BAVMs.Reversal of AVM by Normalization of the Causal Notch Lesion in MiceCorrection of a molecular lesion allows the regression of existing BAVMs and leads to the restoration of AV specification in an animal model. In the Notch4* model, symptoms of AVM are eliminated on suppression of the Notch4* transgene,28 along with rapid regression of the AV shunts, restoration of blood flow to distal arteries, and perfusion of the brain parenchyma (Figure 4C).29 In addition, normal AV specification is restored in concert with the regression of existing Notch4* AVMs—overexpression of arterial markers (Efnb2, Dll4, Jag1, and Cx40) is decreased, and venous marker expression (Ephb4) is restored (Figure 3D). The normalization of these high-flow AV shunts by a single genetic correction has conceptually changed our view on AVM treatment. The discovery that suppression of a causal gene can lead to AVM regression in mice, without hemorrhage or thrombosis, may change the way we think about AVM pathogenesis and treatment.Concluding RemarksMouse models of human BAVM disease provide a useful platform for elucidating the mechanisms of AVM pathogenesis and for exploring treatment options. Moving forward, the identification of additional genetic perturbations associated with BAVM, through continued investigation of both mouse and human genetic studies, will open new opportunities for the rational design and development of better treatment options for this disease.Sources of FundingThis work was supported by National Institutes of Health (NIH) NS067420 and HL075033, Vascular Cures (formerly the Pacific Vascular Research Foundation), the Frank A. Campini Foundation, the Mildred V Strouss Trust, as well as American Heart Association (AHA) grant-in-aid 10GRNT4170146 and GRNT 16850032 to Dr Wang; Tobacco-Related Disease Research Program (TRDRP) 20FT-0069 and NIH 1F32HL110724-01A1 Postdoctoral Fellowships to Dr Nielsen; AHA 0715062Y and TRDRP 18DT-0009 Predoctoral Fellowships to Dr Murphy.DisclosuresNone.Footnotes*Drs Nielsen and Huang contributed equally.The online-only Data Supplement is available with this article at http://stroke.ahajournals.org/lookup/suppl/doi:10.1161/STROKEAHA.115.002869/-/DC1.Correspondence to Rong A. Wang, PhD, Department of Surgery, University of California, San Francisco, 513 Parnassus Ave, HSW 1618, San Francisco, CA 94143. E-mail [email protected]References1. Hartmann A, Mast H, Mohr JP, Koennecke HC, Osipov A, Pile-Spellman J, et al. Morbidity of intracranial hemorrhage in patients with cerebral arteriovenous malformation.Stroke. 1998; 29:931–934.LinkGoogle Scholar2. Morris Z, Whiteley WN, Longstreth WT, Weber F, Lee YC, Tsushima Y, et al. Incidental findings on brain magnetic resonance im" @default.
• W1657646300 created "2016-06-24" @default.
• W1657646300 creator A5024393630 @default.
• W1657646300 creator A5057642594 @default.
• W1657646300 creator A5084996153 @default.
• W1657646300 creator A5089312606 @default.
• W1657646300 creator A5090880715 @default.
• W1657646300 date "2016-01-01" @default.
• W1657646300 modified "2023-09-25" @default.
• W1657646300 title "Mouse Models of Cerebral Arteriovenous Malformation" @default.
• W1657646300 cites W1576609386 @default.
• W1657646300 cites W1858061569 @default.
• W1657646300 cites W1964556578 @default.
• W1657646300 cites W1970826769 @default.
• W1657646300 cites W1975522586 @default.
• W1657646300 cites W1978753072 @default.
• W1657646300 cites W1980856150 @default.
• W1657646300 cites W1983322974 @default.
• W1657646300 cites W1998279502 @default.
• W1657646300 cites W1999470499 @default.
• W1657646300 cites W2014415717 @default.
• W1657646300 cites W2021605609 @default.
• W1657646300 cites W2021659118 @default.
• W1657646300 cites W2026066037 @default.
• W1657646300 cites W2027760929 @default.
• W1657646300 cites W2032686344 @default.
• W1657646300 cites W2035282407 @default.
• W1657646300 cites W2042093530 @default.
• W1657646300 cites W2045851446 @default.
• W1657646300 cites W2053728895 @default.
• W1657646300 cites W2056825102 @default.
• W1657646300 cites W2060168138 @default.
• W1657646300 cites W2060372234 @default.
• W1657646300 cites W2063437420 @default.
• W1657646300 cites W2070755192 @default.
• W1657646300 cites W2075998623 @default.
• W1657646300 cites W2078717028 @default.
• W1657646300 cites W2087323994 @default.
• W1657646300 cites W2090539783 @default.
• W1657646300 cites W2097488679 @default.
• W1657646300 cites W2100523257 @default.
• W1657646300 cites W2100788029 @default.
• W1657646300 cites W2102766489 @default.
• W1657646300 cites W2108668719 @default.
• W1657646300 cites W2116414309 @default.
• W1657646300 cites W2121052913 @default.
• W1657646300 cites W2124245848 @default.
• W1657646300 cites W2127551299 @default.
• W1657646300 cites W2130774572 @default.
• W1657646300 cites W2131246162 @default.
• W1657646300 cites W2131896620 @default.
• W1657646300 cites W2141163534 @default.
• W1657646300 cites W2155495006 @default.
• W1657646300 cites W2160489211 @default.
• W1657646300 cites W2162952004 @default.
• W1657646300 cites W2164903526 @default.
• W1657646300 cites W2166957333 @default.
• W1657646300 cites W2168558463 @default.
• W1657646300 cites W2416542169 @default.
• W1657646300 cites W4210412627 @default.
• W1657646300 cites W4253176626 @default.
• W1657646300 doi "https://doi.org/10.1161/strokeaha.115.002869" @default.
• W1657646300 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5283908" @default.
• W1657646300 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26351360" @default.
• W1657646300 hasPublicationYear "2016" @default.
• W1657646300 type Work @default.
• W1657646300 sameAs 1657646300 @default.
• W1657646300 citedByCount "18" @default.
• W1657646300 countsByYear W16576463002018 @default.
• W1657646300 countsByYear W16576463002019 @default.
• W1657646300 countsByYear W16576463002020 @default.
• W1657646300 countsByYear W16576463002021 @default.
• W1657646300 countsByYear W16576463002022 @default.
• W1657646300 countsByYear W16576463002023 @default.
• W1657646300 crossrefType "journal-article" @default.
• W1657646300 hasAuthorship W1657646300A5024393630 @default.
• W1657646300 hasAuthorship W1657646300A5057642594 @default.
• W1657646300 hasAuthorship W1657646300A5084996153 @default.
• W1657646300 hasAuthorship W1657646300A5089312606 @default.
• W1657646300 hasAuthorship W1657646300A5090880715 @default.
• W1657646300 hasBestOaLocation W16576463001 @default.
• W1657646300 hasConcept C105702510 @default.
• W1657646300 hasConcept C126838900 @default.
• W1657646300 hasConcept C127413603 @default.
• W1657646300 hasConcept C164705383 @default.
• W1657646300 hasConcept C2779603958 @default.
• W1657646300 hasConcept C2780645631 @default.
• W1657646300 hasConcept C71924100 @default.
• W1657646300 hasConcept C78519656 @default.
• W1657646300 hasConceptScore W1657646300C105702510 @default.
• W1657646300 hasConceptScore W1657646300C126838900 @default.
• W1657646300 hasConceptScore W1657646300C127413603 @default.
• W1657646300 hasConceptScore W1657646300C164705383 @default.
• W1657646300 hasConceptScore W1657646300C2779603958 @default.
• W1657646300 hasConceptScore W1657646300C2780645631 @default.
• W1657646300 hasConceptScore W1657646300C71924100 @default.
• W1657646300 hasConceptScore W1657646300C78519656 @default.
• W1657646300 hasIssue "1" @default.

• next